Sun Pharma Acquires Pola Pharma in Japan

Sun Pharma has acquired Pola Pharma, a Japanese pharmaceutical company involved in research and development, manufacture, sale and distribution of branded and generic products in Japan. The portfolio of Pola Pharma primarily comprises dermatology products.
 
Pola Pharma, part of Pola Orbis Group, has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. It also has R&D capabilities to develop new technologies and formulations.
 
"This acquisition is in line with our strategy to strengthen our global dermatology presence," said Kirti Ganorkar, executive vice president, Sun Pharma. "Pola Pharma is a leading dermatology company and it will help us to launch our specialty and generic dermatology products in the Japanese market in the future. We also get access to local manufacturing capability enabling us to serve the Japanese pharmaceutical market more effectively."
 
Junichi Nakamichi, country head of Japan, Sun Pharma, "By combining Sun Pharma’s global strengths with Pola Pharma’s local expertise, we will have a great opportunity to further strengthen our presence in Japan, especially in the area of dermatology."
 
Pola Pharma had annual revenues of approximately $108 million in 2017. 
 
Sun Pharma forayed into the Japanese prescription market in 2016 with the acquisition of 14 established prescription brands from Novartis. The size of the Japanese pharmaceutical market is estimated at $84.8 billion, accounting for approximately 7.5% of the $1.13 trillion global pharmaceutical market, according to IQVIA Market Prognosis, September 2017.

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.